<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627287</url>
  </required_header>
  <id_info>
    <org_study_id>INS-4208</org_study_id>
    <secondary_id>2014-004802-13</secondary_id>
    <secondary_id>U1111-1163-5039</secondary_id>
    <nct_id>NCT02627287</nct_id>
  </id_info>
  <brief_title>A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®</brief_title>
  <official_title>A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare Injections with the
      Medical Device DV3316 Pen-injector versus FlexPen®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Actual">February 25, 2016</completion_date>
  <primary_completion_date type="Actual">February 25, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection success (full dose delivered s.c.) (yes/no)</measure>
    <time_frame>By assessment that the dose counter has returned to &quot;0&quot; (EoD confirmation) for the DV3316 pen-injector and for FlexPen® at least 6 seconds after the dose counter has returned to &quot;0&quot;</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects' confidence in injection completion (delivery of correct, full dose)</measure>
    <time_frame>Injection completed within 2 minutes after needle insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of liquid on the skin (placebo solution or tissue fluid)</measure>
    <time_frame>Injection completed within 2 minutes after needle insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' reaction time</measure>
    <time_frame>Injection completed within 2 minutes after needle insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects evaluation of pen-injector experience</measure>
    <time_frame>Injections completed within 2 minutes of needle insertion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of technical complaints</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse device effects</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of bleeding, redness, bruising and swelling at the site of injection</measure>
    <time_frame>Within 10 minutes after completion of injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of bleeding, redness, bruising and swelling at the site of injection</measure>
    <time_frame>1 hour after completion of injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>DV3316 pen-injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FlexPen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FlexPen®</intervention_name>
    <description>For subcutaneously (s.c. under the skin) injection.</description>
    <arm_group_label>FlexPen®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DV3316 pen-injector</intervention_name>
    <description>For subcutaneously (s.c. under the skin) injection.</description>
    <arm_group_label>DV3316 pen-injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>For subcutaneously (s.c. under the skin) injection</description>
    <arm_group_label>DV3316 pen-injector</arm_group_label>
    <arm_group_label>FlexPen®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18-74 years (both included) at the time of signing informed
             consent

          -  T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) (as diagnosed
             clinically) at least 12 months prior to screening

          -  Daily self-injection(s) with anti-diabetic drug (insulin or Glucagon-Like Peptide-1
             (GLP- 1) analogues) in pen-injector or vial/syringe for at least 12 months

          -  Caucasians

          -  Body Mass Index (BMI) at least 18.5 kg/m^2

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to test placebo solution incl. m-cresol and phenol
             or related products (placebo)

          -  Female who is pregnant,, breast-feeding or intends to become pregnant or is of
             childbearing potential and not using adequate contraceptive methods (adequate
             contraceptive measures as required by local law or practice)

          -  Known urticaria factitive or abnormal reactions to mechanical trauma

          -  Haemophilia and any diseases affecting blood coagulation

          -  Anti-coagulant or inhibitors of platelet aggregation treatment on the day of the visit

          -  Intake of any pain-relieving or analgesic drugs on the day of the site visit

          -  Skin diseases and infections of the skin in the injection site areas (abdomen and
             thighs)

          -  Lipodystrophia in the injection site areas (abdomen and thighs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L, Wang T. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. Diabetes Obes Metab. 2018 May;20(5):1262-1279. doi: 10.1111/dom.13232. Epub 2018 Feb 23.</citation>
    <PMID>29369494</PMID>
  </results_reference>
  <results_reference>
    <citation>Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T. Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism. Diabetes Obes Metab. 2018 May;20(5):1140-1147. doi: 10.1111/dom.13203. Epub 2018 Jan 25.</citation>
    <PMID>29369493</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

